Huntington's disease

doi:10.1017/CBO9780511544873.058

57 - Huntington's disease

from Part X - Other neurodegenerative diseases

Published online by Cambridge University Press: 04 August 2010

M. Flint Beal ,

Anthony E. Lang and

Albert C. Ludolph

Christoph M. Kosinski and

Bernhard Landwehrmeyer

Show author details

M. Flint Beal: Affiliation:
Cornell University, New York
Anthony E. Lang: Affiliation:
University of Toronto
Albert C. Ludolph: Affiliation:
Universität Ulm, Germany
Christoph M. Kosinski: Affiliation:
Department of Neurology, University Hospital Aachen, Germany
Bernhard Landwehrmeyer: Affiliation:
Department of Neurology, University of Ulm, Germany

Book contents

Get access

Summary

Introduction

The description by George Huntington in 1872 of the disease that has subsequently borne his name is remarkable for its clarity and comprehensiveness (Huntington, 1872). It was not the first description of the disorder (see, for instance, Charles Oscar Waters, 1842, and Johan Christian Lund, 1860) (Waters, 1842; Lund, 1860), but it stands out as the first full delineation of the condition as a specific disease entity, quite separate from other forms of chorea. Huntington's paper was given at Middleport, Ohio, and published later in the Philadelphia journal, The Medical and Surgical Reporter. One can do no better than quote it here:

The hereditary chorea, as I shall call it, is confined to certain and fortunately a few families, and has been transmitted to them, an heirloom from generations away back in the dim past. It is spoken of by those in whose veins the seeds of the disease are known to exist, with a kind of horror, and not at all alluded to except through dire necessity, when it is mentioned as ‘that disorder’. It is attended generally by all the symptoms of common chorea, only in an aggravated degree hardly ever manifesting itself until adult or middle life, and then coming on gradually but surely, increasing by degrees, and often occupying years in its development, until the hapless sufferer is but a quivering wreck of his former self. (…) There are three marked peculiarities in this disease: 1. Its hereditary nature. 2. A tendency to insanity and suicide.[…]

Type: Chapter
Information: Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 847 - 860

DOI: https://doi.org/10.1017/CBO9780511544873.058 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Albin, R. L., Young, A. B. & Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci., 12, 366–75CrossRef Google Scholar PubMed

Andrew, S. E., Goldberg, Y. P., Kremer, B.et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet., 4, 398–403CrossRef Google Scholar PubMed

Andrew, S. E., Goldberg, Y. P., Kremer, B.et al. (1994a). Huntington disease without CAG expansion: phenocopies or errors in assignment?Am. J. Hum. Genet., 54, 852–63Google Scholar

Andrew, S. E., Goldberg, Y. P., Theilmann, J., Zeisler, J. & Hayden, M. R. (1994b). A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum. Mol. Genet., 3, 65–7CrossRef Google Scholar

Ashizawa, T., Wong, L. J., Richards, C. S., Caskey, C. T. & Jankovic, J. (1994). CAG repeat size and clinical presentation in Huntington's disease. Neurology, 44, 1137–43CrossRef Google Scholar PubMed

Bamford, K. A., Caine, E. D., Kido, D. K., Cox, C. & Shoulson, I. (1995). A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology, 45, 1867–73CrossRef Google Scholar PubMed

Barron, L. H., Rae, A., Holloway, S., Brock, D. J. & Warner, J. P. (1994). A single allele from the polymorphic CCG rich sequence immediately 3′ to the unstable CAG trinucleotide in the IT15 cDNA shows almost complete disequilibrium with Huntington's disease chromosomes in the Scottish population. Hum. Mol. Genet., 3, 173–5CrossRef Google Scholar PubMed

Bauer, P., Laccone, F., Rolfs, A.et al.(2004). Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J. Med. Genet., 41, 230–2CrossRef Google Scholar PubMed

Beal, M. F. (1995). Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol., 38, 357–66CrossRef Google Scholar PubMed

Beenen, N., Buttner, U. & Lange, H. W. (1986). The diagnostic value of eye movement recordings in patients with Huntington's disease and their offspring. Electroencephalogr. Clin. Neurophysiol., 63, 119–27CrossRef Google Scholar PubMed

Behrens, P. F., Franz, P., Woodman, B., Lindenberg, K. S. & Landwehrmeyer, G. B. (2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain, 125, 1908–22CrossRef Google Scholar PubMed

Bots, G. T. & Bruyn, G. W. (1981). Neuropathological changes of the nucleus accumbens in Huntington's chorea. Acta Neuropathol. (Berl.), 55, 21–2CrossRef Google Scholar PubMed

Boutell, J. M., Thomas, P., Neal, J. W.et al. (2004). Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet., 1999, 1647Google Scholar

Brandt, J., Strauss, M. E., Larus, J., Jensen, B., Folstein, S. E. & Folstein, M. F. (1984). Clinical correlates of dementia and disability in Huntington's disease. J. Clin. Neuropsychol., 6, 401–12CrossRef Google Scholar

Brandt, J., Bylsma, F., Gross, R., Stine, O., Ranen, N. & Ross, C. (1996). Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology, 46, 531–5CrossRef Google Scholar PubMed

Brinkman, R. R., Mezei, M. M., Theilmann, J., Almqvist, E. & Hayden, M. R. (1997). The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am. J. Hum. Genet., 60, 1202–10Google Scholar PubMed

Browne, S. E., Ferrante, R. J. & Beal, M. F. (1999). Oxidative stress in Huntington's disease. Brain Pathol., 9, 147–63CrossRef Google Scholar PubMed

Bruyn, G. W. (1979). [Huntington's chorea]. Tijdschr. Ziekenverpl., 32, 101–5Google Scholar

Butters, N., Wolfe, J., Granholm, E. & Martone, M. (1986). An assessment of verbal recall, recognition and fluency abilities in patients with Huntington's disease. Cortex, 22, 11–32CrossRef Google Scholar PubMed

Bylsma, F. W., Rebok, G. W. & Brandt, J. (1991). Long-term retention of implicit learning in Huntington's disease. Neuropsychologia, 29, 1213–21CrossRef Google Scholar PubMed

Cepeda, C., Ariano, M. A., Calvert, C. R.et al. (2001). NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res., 66, 525–39CrossRef Google Scholar PubMed

Cha, J. H.. (2000). Transcriptional dysregulation in Huntington's disease. Trends Neurosci., 23, 387–92CrossRef Google Scholar PubMed

Cha, J. H., Kosinski, C. M., Kerner, J. A.et al. (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl Acad. Sci. USA, 95(11), 6480–5CrossRef Google Scholar PubMed

Cha, J. H., Frey, A. S., Alsdorf, S. A.et al. (1999). Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. R. Soc. Lond. B Biol. Sci., 354, 981–9CrossRef Google Scholar PubMed

Chen, M., Ona, V. O., Li, M.et al. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease. Nat. Med., 6, 797–801Google Scholar

Chen, S., Ferrone, F. A. & Wetzel, R. (2002). Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl Acad. Sci., USA, 99, 11884–9CrossRef Google Scholar PubMed

Chong, S. S., Almqvist, E., Telenius, H.et al. (1997). Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Hum. Mol. Genet., 6, 301–9CrossRef Google Scholar PubMed

Claes, S., Zand, K., Legius, E.et al. (1995). Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch. Neurol., 52, 749–53CrossRef Google Scholar PubMed

Critchley, E. M., Clark, D. B. & Wikler, A. (1967). An adult form of acanthocytosis. Trans. Am. Neurol. Assoc., 92, 132–7Google Scholar PubMed

Crossman, A. R.. (1987). Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience, 21, 1–40CrossRef Google Scholar

Cummings, C. J. & Zoghbi, H. Y. (2000). Trinucleotide repeats: mechanisms and pathophysiology. Annu. Rev. Genom. Hum. Genet., 1, 281–328CrossRef Google Scholar PubMed

Curra, A., Agostino, R., Galizia, P., Fittipaldi, F., Manfredi, M. & Berardelli, A. (2000). Sub-movement cueing and motor sequence execution in patients with Huntington's disease. Clin. Neurophysiol., 111, 1184–90CrossRef Google Scholar PubMed

Curtis, A. R., Fey, C., Morris, C. M.et al. (2001). Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet., 28, 350–4CrossRef Google Scholar PubMed

Danek, A., Tison, F., Rubio, J., Oechsner, M., Kalckreuth, W. & Monaco, A. P. (2001). The chorea of McLeod syndrome. Mov. Disord., 16, 882–9CrossRef Google Scholar PubMed

Davies, S., Turmaine, M., Cozens, B.et al. (1997). Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537–48CrossRef Google Scholar

Davis, M. B., Bateman, D., Quinn, N. P., Marsden, C. D. & Harding, A. E. (1994). Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet, 344, 714–17CrossRef Google Scholar PubMed

Boo, G., Tibben, A., Hermans, J., Maat, A. & Roos, R. A. (1998). Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov. Disord., 13, 96–9CrossRef Google Scholar

Dedeoglu, A., Kubilus, J. K., Yang, L.et al. (2003). Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem., 85, 1359–67CrossRef Google Scholar PubMed

DiFiglia, M., Sapp, E., Chase, K.et al. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990–3CrossRef Google Scholar PubMed

Dunah, A. W., Jeong, H., Griffin, A.et al. (2002). Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238–43CrossRef Google Scholar PubMed

Duyao, M., Ambrose, C. & Myers, R. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet., 4, 387–92CrossRef Google Scholar PubMed

Farrer, L. A. (1985). Diabetes mellitus in Huntington disease. Clin. Genet., 27(1), 62–7CrossRef Google Scholar PubMed

Feigin, A., Kieburtz, K., Bordwell, K.et al. (1995). Functional decline in Huntington's disease. Mov. Disord., 10, 211–14CrossRef Google Scholar PubMed

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G.et al. (2000). Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci., 20, 4389–97CrossRef Google Scholar

Ferrante, R. J., Kubilus, J. K., Lee, J.et al. (2004). Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 9418–27CrossRef Google Scholar

Folstein, S. E., Jensen, B., Leigh, R. J. & Folstein, M. F. (1983). The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav. Toxicol. Teratol., 5, 605–9Google Scholar PubMed

Forno, L. S. & Norville, R. L. (1979). Ultrastructure of the neostriatum in Huntington's and Parkinson's disease. Adv. Neurol., 23, 123–39Google Scholar

Friedlander, R. M. (2003). Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med., 348, 1365–75CrossRef Google Scholar PubMed

Garcia Ruiz, P. J., Gomez-Tortosa, E., del Barrio, A.et al. (1997). Senile chorea: a multicenter prospective study. Acta Neurol. Scand., 95, 180–3CrossRef Google Scholar PubMed

Gellera, C., Meoni, C., Castellotti, B.et al. (1996). Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am. J. Hum. Genet., 59, 475–7Google Scholar PubMed

Georgiou, N., Phillips, J. G., Bradshaw, J. L., Cunnington, R. & Chiu, E. (1997). Impairments of movement kinematics in patients with Huntington's disease: a comparison with and without a concurrent task. Mov. Disord., 12, 386–96CrossRef Google Scholar PubMed

Goldberg, Y. P., Andrew, S. E., Theilmann, J.et al. (1993). Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. J. Med. Genet., 30, 987–90CrossRef Google Scholar PubMed

Gusella, J. F., Wexler, N. S., Conneally, P. M.et al. (1983). A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 306, 234–8CrossRef Google Scholar PubMed

Gusella, J. F., Tanzi, R. E., Bader, P. I.et al. (1985). Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf–Hirschhorn syndrome. Nature, 318, 75–8CrossRef Google Scholar PubMed

Haines, J. L. & Conneally, P. M. (1986). Causes of death in Huntington disease as reported on death certificates. Genet. Epidemiol., 3, 417–23CrossRef Google Scholar PubMed

Hardie, R. J., Pullon, H. W., Harding, A. E.et al. (1991). Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain, 114(Pt 1A), 13–49Google Scholar PubMed

Hefter, H., Homberg, V., Lange, H. W. & Freund, H. J. (1987). Impairment of rapid movement in Huntington's disease. Brain, 110(3), 585–612CrossRef Google Scholar PubMed

Heinsen, H., Strik, M., Bauer, M.et al. (1994). Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol., 88, 320–33CrossRef Google Scholar PubMed

Hickey, M. A. & Chesselet, M.-F. (2003). Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatr., 27, 255–65CrossRef Google Scholar PubMed

Higgins, J. J., Patterson, M. C., Papadopoulos, N. M., Brady, R. O., Pentchev, P. G. & Barton, N. W. (1992). Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology, 42, 194–8CrossRef Google Scholar

Hockly, E., Richon, V. M., Woodman, B., et al. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci., USA, 100, 2041–6CrossRef Google Scholar

Hoffmann, J. (1888). Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchow's Archiv für Pathol. Anat., 111, 513–48CrossRef Google Scholar

Holbert, S., Denghien, I., Kiechle, T.et al. (2001). The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl Acad. Sci., USA, 98, 1811–16CrossRef Google Scholar PubMed

Huntington, G. (1872). On chorea. Med. Surg. Rep., 26, 317–21Google Scholar

Huntington Study Group (1996). Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord., 11, 136–42CrossRef

Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971–83CrossRef

Jelgersma, G. (1908). Die anatomischen Veränderungen bei Paralysis agitans und chronischer Chorea. Verh. Ges. Dtsch. Naturforsch. Ärzt., 2, 383–8Google Scholar

Kambouris, M., Bohlega, S., Al Tahan, A. & Meyer, B. F. (2000). Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am. J. Hum. Genet., 66, 445–52CrossRef Google Scholar PubMed

Kehoe, P., Krawczak, M., Harper, P. S., Owen, M. J. & Jones, A. L. (1999). Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet., 36, 108–11Google Scholar PubMed

Kieburtz, K., MacDonald, M., Shih, C.et al. (1994). Trinucleotide repeat length and progression of illness in Huntington's disease. J. Med. Genet., 31, 872–4CrossRef Google Scholar PubMed

Kirkwood, S. C., Siemers, E., Hodes, M. E., Conneally, P. M., Christian, J. C. & Foroud, T. (2000). Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatr., 69, 773–9CrossRef Google Scholar PubMed

Koller, W. C. & Trimble, J. (1985). The gait abnormality of Huntington's disease. Neurology, 35, 1450–4CrossRef Google Scholar PubMed

Koroshetz, W. J., Jenkins, B. G., Rosen, B. R. & Beal, M. F. (1997). Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol., 41, 160–5CrossRef Google Scholar PubMed

Kovtun, I. V. & McMurray, C. T. (2001). Trinucleotide expansion in haploid germ cells by gap repair. Nat. Genet., 27, 407–11CrossRef Google Scholar PubMed

Kremer, B., Almqvist, E., Theilmann, J.et al. (1995). Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am. J. Hum. Genet., 57, 343–50Google Scholar PubMed

Kremer, B., Clark, C. M., Almqvist, E. W.et al. (1999). Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology, 53, 1000–11CrossRef Google Scholar PubMed

Kremer, H. P. & Roos, R. A. (1992). Weight loss in Huntington's disease. Arch. Neurol., 49, 349CrossRef Google Scholar PubMed

Landwehrmeyer, G. B., McNeil, S. M., Dure, L. S.et al. (1995). Huntington's Disease Gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol., 37, 218–30CrossRef Google Scholar PubMed

Lanska, D. J., Lanska, M. J., Lavine, L. & Schoenberg, B. S. (1988). Conditions associated with Huntington's disease at death. A case-control study. Arch. Neurol., 45, 878–80CrossRef Google Scholar PubMed

Lasker, A. G. & Zee, D. S. (1997). Ocular motor abnormalities in Huntington's disease. Vision Res., 37, 3639–45CrossRef Google Scholar PubMed

Lasker, A. G., Zee, D. S., Hain, T. C., Folstein, S. E. & Singer, H. S. (1998). Saccades in Huntington's disease: slowing and dysmetria. Neurology, 38, 427–31CrossRef Google Scholar

Leeflang, E. P., Zhang, L., Tavare, S.et al. (1995). Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum. Molec. Genet., 4, 1519–26CrossRef Google Scholar PubMed

Li, J. L., Hayden, M. R., Almqvist, E. W.et al. (2003). A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am. J. Hum. Genet., 73, 682–7CrossRef Google Scholar

Li, S. H., Schilling, G., Young, W.3et al. (1993). Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron, 11, 985–93CrossRef Google Scholar PubMed

Li, S. H., Cheng, A. L., Zhou, H.et al. (2002). Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol., 22, 1277–87CrossRef Google Scholar PubMed

Losekoot, M., Bakker, B., Laccone, F., Stenhouse, S. & Elles, R. (1999). A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease. Eur. J. Hum. Genet., 7, 217–22CrossRef Google Scholar PubMed

Louis, E. D., Marder, K., Moskowitz, C. & Greene, P. (1999). Arm elevation in Huntington's disease: dystonia or levitation?Mov. Disord., 14, 1035–83.0.CO;2-D>CrossRef Google Scholar PubMed

Louis, E. D., Anderson, K. E., Moskowitz, C., Thorne, D. Z. & Marder, K. (2000). Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. Arch. Neurol., 57, 1326–30CrossRef Google Scholar PubMed

Lund, J. C. (1860). Chorea St Vitus Dance in Saetersdalen. In Quoted by Orbeck 1, ed. p. 137

MacMillan, J. C., Snell, R. G., Tyler, A.et al. (1993). Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet, 342, 954–958CrossRef Google Scholar PubMed

Mahadevan, M., Tsilfidis, C., Sabourin, L.et al. (1992). Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science, 255, 1253–5CrossRef Google Scholar PubMed

Mandich, P.,Di Maria, E., Bellone, E., Ajmar, F. & Abbruzzese, G. (1996). Molecular analysis of the IT15 gene in patients with apparently ‘sporadic’ Huntington's disease. Eur. Neurol., 36, 348–52CrossRef Google Scholar PubMed

Mangiarini, L., Sathasivam, K., Seller, M.et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493–506CrossRef Google Scholar

Marder, K., Zhao, H., Myers, R. H.et al. (2000). Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology, 54, 452–58CrossRef Google Scholar PubMed

Margolis, R. L., O'Hearn, E., Rosenblatt, A.et al. (2001). A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann. Neurol., 50, 373–80CrossRef Google Scholar PubMed

Mars, H., Lewis, L. A., Robertson, A. L. Jr., Butkus, A. & Williams, G. H. Jr. (1969). Familial hypo-beta-lipoproteinemia: a genetic disorder of lipid metabolism with nervous system involvement. Am. J. Med., 46, 886–900CrossRef Google Scholar PubMed

McComas, A. J., Sica, R. E. & Toyonaga, K. (1978). Incidence, severity, and time-course of motoneurone dysfunction in myotonic dystrophy: their significance for an understanding of anticipation. J. Neurol. Neurosurg. Psychiatr., 41, 882–93CrossRef Google Scholar PubMed

Moore, R. C., Xiang, F., Monaghan, J.et al. (2001). Huntington disease phenocopy is a familial prion disease. Am. J. Hum. Genet., 69, 1385–8CrossRef Google Scholar PubMed

Morales, L. M., Estevez, J., Suarez, H., Villalobos, R., Chacin, D. B. & Bonilla, E. (1989). Nutritional evaluation of Huntington disease patients. Am. J. Clin. Nutr., 50, 145–50CrossRef Google Scholar PubMed

Myers, R. H., Vonsattel, J. P., Stevens, T. J.et al. (1988). Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology, 38, 341–7CrossRef Google Scholar PubMed

Myers, R. H., Sax, D. S., Koroshetz, W. J.et al. (1991). Factors associated with slow progression in Huntington's disease. Arch. Neurol., 48, 800–4CrossRef Google Scholar PubMed

Myers, R. H., MacDonald, M. E., Koroshetz, W. J.et al. (1993). De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet., 5, 168–73CrossRef Google Scholar PubMed

Nance, M. A. (1998). Huntington disease: clinical, genetic, and social aspects. J. Geriatr. Psychiatry Neurol., 11, 61–70CrossRef Google Scholar PubMed

Nucifora, F. C.., Sasaki, M., Peters, M. F.et al. (2001). Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423–8CrossRef Google Scholar PubMed

Oepen, G., Clarenbach, P. & Thoden, U. (1981). Disturbance of eye movements in Huntington's chorea. Arch. Psychiatr. Nervenkr., 229, 205–13Google Scholar PubMed

Panas, M., Avramopoulos, D., Karadima, G., Petersen, M. B. & Vassilopoulos, D. (1999). Apolipoprotein E and presenilin-1 genotypes in Huntington's disease. J. Neurol., 246, 574–7CrossRef Google Scholar PubMed

Panov, A. V., Gutekunst, C.-A., Leavitt, B.et al. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731–6CrossRef Google Scholar PubMed

Penney, J. B. Jr., Young, A. B., Shoulson, I.et al. (1990). Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord., 5, 93–9CrossRef Google Scholar PubMed

Penney, J. B.., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. (1997). CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol., 41, 689–92CrossRef Google Scholar PubMed

Perutz, M. (1996). Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol., 6, 848–58CrossRef Google Scholar PubMed

Phillips, J. G., Bradshaw, J. L., Chiu, E., Teasdale, N., Iansek, R. & Bradshaw, J. A. (1996). Bradykinesia and movement precision in Huntington's disease. Neuropsychologia, 34, 1241–45CrossRef Google Scholar PubMed

Pickering, D. S., Thomsen, C., Suzdak, P. D.et al. (1993). A comparison of two alternatively spliced forms of a metabotropic glutamate receptor coupled to phosphoinositide turnover. J. Neurochem., 61, 85–92CrossRef Google Scholar PubMed

Pratley, R. E., Salbe, A. D., Ravussin, E. & Caviness, J. N. (2000). Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol., 47, 64–703.0.CO;2-S>CrossRef Google Scholar PubMed

Quinn, N. & Schrag, A. (1998). Huntington's disease and other choreas. J. Neurol., 245, 709–16CrossRef Google Scholar PubMed

Ranen, N., Stine, O., Abbot, M.et al. (1995). Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am. J. Hum. Genet., 57, 593–602Google Scholar PubMed

Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B. & Young, A. B. (1988). Differential loss of striatal projection neurons in Huntington disease. Proc. Natl Acad. Sci., USA, 85, 5733–7CrossRef Google Scholar PubMed

Roizin, L., Stellar, S., & Liu, J. (1979). Neuronal nuclear-cytoplasmic changes in Huntingtons chorea: electron microscope investigations. In Advance in Neurology, Huntington's Disease, ed. N. Wexler & A. Barbeau, New York: Raven Press. pp. 195–22

Roos, R. A., Pruyt, J. F., Vries, J. & Bots, G. T. (1985). Neuronal distribution in the putamen in Huntington's disease. J. Neurol. Neurosurg. Psychiatr., 48, 422–5CrossRef Google Scholar PubMed

Rosenblatt, A., Brinkman, R. R., Liang, K. Y. (2001). Familial influence on age of onset among siblings with Huntington disease. Am. J. Med. Genet., 105, 399–403CrossRef Google Scholar PubMed

Ross, C. A. (2002). Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron, 35, 819–22CrossRef Google Scholar PubMed

Rubinsztein, D. C., Leggo, J., Barton, D. E. & Ferguson-Smith, M. A. (1993). Site of (CCG) polymorphism in the HD gene. Nat. Genet., 5, 214–15CrossRef Google Scholar PubMed

Rubinsztein, D. C., Leggo, J., Coles, R.et al. (1996). Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am. J. Hum. Genet., 59, 16–22Google Scholar PubMed

Rubinsztein, D. C., Leggo, J., Chiano, M.et al. (1997). Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc. Natl Acad. Sci., USA, 94, 3872–6CrossRef Google Scholar PubMed

Sanberg, P. R., Fibiger, H. C. & Mark, R. F. (1981). Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1, 407–9Google Scholar PubMed

Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55–66CrossRef Google Scholar

Schapira, A. H. (1999). Mitochondrial involvement in Parkinson's, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochem. Biophys. Act., 1410, 99–102Google Scholar PubMed

Scherzinger, E., Lurz, R., Turmaine, M.et al. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 90, 549–58CrossRef Google Scholar PubMed

Schilling, G., Sharp, A. H., Loev, S. J.et al. (1995). Expression of the Huntington's disease (IT15) protein product in HD patients. Hum. Mol. Genet., 4, 1365–71CrossRef Google Scholar PubMed

Schubotz, R., Hausmann, L., Kaffarnik, H., Zehner, J. & Oepen, H. (1976). Fatty acid patterns and glucose tolerance in Huntington's chorea. Res. Exp. Med. (Berl.), 167(3), 203–15CrossRef Google Scholar PubMed

Schwarz, M., Fellows, S. J., Schaffrath, C. & Noth, J. (2001). Deficits in sensorimotor control during precise hand movements in Huntington's disease. Clin. Neurophysiol., 112, 95–106CrossRef Google Scholar PubMed

Sharp, A. H., Loev, S. J., Schilling, G.et al. (1995). Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 14, 1065–74CrossRef Google Scholar PubMed

Shinotoh, H., Calne, D. B., Snow, B.et al. (1994). Normal CAG repeat length in the Huntington's disease gene in senile chorea. Neurology, 44, 2183–4CrossRef Google Scholar PubMed

Shoulson, I. (1981). Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology, 31, 1333–5CrossRef Google Scholar PubMed

Shoulson, I. & Fahn, S. (1979). Huntington disease: clinical care and evaluation. Neurology, 29, 1–3CrossRef Google Scholar PubMed

Shoulson, I., Odoroff, C., Oakes, D.et al. (1989). A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol., 25, 252–9CrossRef Google Scholar PubMed

Snell, R. G., MacMillan, J. C., Cheadle, J. P.et al. (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet., 4, 393–7CrossRef Google Scholar PubMed

Snowden, J., Craufurd, D., Griffiths, H., Thompson, J. & Neary, D. (2001). Longitudinal evaluation of cognitive disorder in Huntington's disease. J. Int. Neuropsychol. Soc., 7, 33–44CrossRef Google Scholar PubMed

Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O.et al. (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci., USA, 97, 6763–8CrossRef Google Scholar PubMed

Steffan, J. S., Bodai, L., Pallos, J.et al. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739–43CrossRef Google Scholar PubMed

Tanaka, M., Machida, Y., Niu, S.et al. (2004). Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med., 10, 148–54CrossRef Google Scholar

Thompson, P. D., Berardelli, A., Rothwell, J. C.et al. (1988). The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain, 111(2), 223–44CrossRef Google Scholar PubMed

Tian, J. R., Zee, D. S., Lasker, A. G. & Folstein, S. E. (1991). Saccades in Huntington's disease: predictive tracking and interaction between release of fixation and initiation of saccades. Neurology, 41, 875–81CrossRef Google Scholar PubMed

Trottier, Y., Biancalana, V. & Mandel, J. L. (1994). Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J. Med. Genet., 31, 377–82CrossRef Google Scholar PubMed

Vugt, J. P., Hilten, B. J. & Roos, R. A. (1996). Hypokinesia in Huntington's disease. Mov. Disord., 11, 384–88CrossRef Google Scholar PubMed

Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D. & Richardson, E. Jr. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559–77CrossRef Google Scholar PubMed

Vuillaume, I., Meynieu, P., Schraen-Maschke, S., Destee, A. & Sablonniere, B. (2000). Absence of unidentified CAG repeat expansion in patients with Huntington's disease-like phenotype. J. Neurol. Neurosurg. Psychiatr., 68, 672–5CrossRef Google Scholar PubMed

Waters, C. O. (1842). In Practice in Medicine, ed. R. Dunglison. Philadelphia: Lee and Blanchard. p. 312

Wellington, C. L., Brinkman, R. R., Kusky, J. & Hayden, M. R. (1997). Toward understanding the molecular pathology of Huntington's disease. Brain Pathol., 7, 979–1002CrossRef Google Scholar PubMed

Westphal, C. (1883). Über eine dem Bilde der cerebrospinalen grauen Degeneration ähnlichen Erkrankung des centralen Nervensystems ohne anatomischen Befund, nebst einigen Bemerkungen über paradoxe Contractionen. Arch. Psychiatr. Nervenkr., 14, 187–94CrossRef Google Scholar

Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. (2002). Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet., 11, 2905–17CrossRef Google Scholar PubMed

Young, A. B., Shoulson, I., Penney, J. B.et al. (1986). Huntington's disease in Venezuela: neurologic features and functional decline. Neurology, 36, 244–9CrossRef Google Scholar PubMed

Zeron, M. M., Hansson, O., Chen, N.et al. (2002). Increased sensitivity to N-methyl-D-asparta te receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron, 33, 849–60CrossRef Google Scholar

Zuhlke, C., Riess, O., Schroder, K.et al. (1993). Expansion of the (CAG)n repeat causing Huntington's disease in 352 patients of German origin. Hum. Mol. Gene., 2, 1467–9Google Scholar PubMed